Table 1.
Patient characteristics
| Patients | Sex/Age | Pathology | Site of Metastasis | Previous Treatment | i/mDC | HLA |
| 1 | M/47 | Mel | Liver, mediastinal lymph nodes | IFN | iDC | A1A2B8B35Bw6Cw4Cw7 |
| 2 | M/52 | Mel | Liver | BIOCT | iDC | A3A28B35B53Cw4 |
| 3 | M/49 | Mel | Liver, adrenal glands | No treatment | iDC + mDC | A11A31B14B60Bw6Cw3 |
| 4 | M/42 | Mel | Liver, mediastinal and axillary lymph nodes | BIOCT | iDC+ mDC | A1A9B17Bw4Bw6Cw3Cw4 |
| 5 | F/49 | Mel | Lung, lymph nodes, skin, peritoneum | BIOCT | iDC+ mDC | A1A9B7B44Bw4Bw6Cw4Cw7 |
| 6 | M/50 | Renal ca. | Skin, adrenal glands | BIOCT | mDC | A2A3B7B51Bw4Bw6Cw1Cw7 |
| 7 | F/52 | Mel | Lung, liver | HdIFN + CT | mDC | A3A29B44Bw4 |
| 8 | M/46 | Mel | Abdominal lymph nodes | IFN+BIOCT | mDC | A3A28B21B35Cw4 |
IFN, alpha interferon; BIOCT, biochemotherapy; CT, chemotherapy; HdIFN, high-dose adjuvant alpha interferon (ECOG 1684)